Inventor · disambiguated record
Thomas Seewoester
Also filed as: SEEWOESTER THOMAS
9 granted patents·4 pending applications·332 citations·filing 2005–2018
92Inventor score
Top patents by PatentIndex Score
13 records- 0198US9284371B2Methods of producing adalimumabABBVIE INC·Filed 2015·Granted Mar 15, 2016·29 cites·30 claims
- 0297US8906646B2Fed-batch method of making human anti-TNF-alpha antibodyABBVIE INC·Filed 2014·Granted Dec 9, 2014·44 cites·28 claims
- 0396US9234032B2Fed-batch methods for producing adalimumabABBVIE INC·Filed 2014·Granted Jan 12, 2016·21 cites·31 claims
- 0496US9073988B2Fed batch method of making anti-TNF-alpha antibodiesABBVIE INC·Filed 2014·Granted Jul 7, 2015·22 cites·27 claims
- 0596US8911964B2Fed-batch method of making human anti-TNF-alpha antibodyABBVIE INC·Filed 2014·Granted Dec 16, 2014·45 cites·30 claims
- 0696US8093045B2Fed-batch cell culture methods using non-animal-based hydrolysatesPLA ITZCOATL A·Filed 2007·Granted Jan 10, 2012·90 cites·65 claims
- 0795US9090867B2Fed-batch method of making anti-TNF-alpha antibodyABBVIE INC·Filed 2014·Granted Jul 28, 2015·23 cites·30 claims
- 0893US8663945B2Methods of producing anti-TNF-alpha antibodies in mammalian cell culturePLA ITZCOATL A·Filed 2011·Granted Mar 4, 2014·56 cites·39 claims
- 0987US10119118B2Modified serum-free cell culture mediumABBVIE INC·Filed 2016·Granted Nov 6, 2018·2 cites·1 claims
- 1072US2019225934A1Cell culture improvementsABBVIE INC·Filed 2018·Application pending·0 cites
- 1168US2015125905A1Cell culture improvementsABBVIE INC·Filed 2014·Application pending·0 cites
- 1265US2016186130A1Cell culture improvementsABBVIE INC·Filed 2016·Application pending·0 cites
- 1341US2006115901A1Method and media for single cell serum-free culture of CHO cellsVALAMEHR BAHRAM·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Thomas Seewoester files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →